Pharmaceutical

Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial
FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
Regenxbio Touts Positive Biomarker Data From Duchenne Muscular Dystrophy Gene Therapy Trial
FDA Grants Fast Track Review To Johnson & Johnson's Nipocalimab For Autoimmune Disorder That Affects Tears, Saliva
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
FDA Rejects Johnson & Johnson's Injectable Version Of Approved Drug For Lung Cancer

Pharmaceutical Recent News

Stock Of The Day: Here's Why Weight-Loss Drug Maker Eli Lilly Has Reversed
Shares of Eli Lilly hit resistance at the $955 level. Now they are heading lower. These moves are due to investor psychology.
What's Going On With Eli Lilly and Company Shares Friday
Eli Lilly is anticipated to release earnings on August 8 for the 2024 fiscal year second quarter.
Stock Of The Day: Moderna Stock Plunges, Breaking Key Support Levels Following Earnings Report
Shares of Moderna (MRNA) have broken an important support level. This means a new downtrend may be forming.
Why Evoke Pharma (EVOK) Stock Is Volatile
Evoke Pharma shares were trading lower by 21.4% during Tuesday's session. The company announced a 1-for-12 reverse stock split of its common stock.
Teva's Migraine Treatment Found Effective For Children As Young As 6
Teva Pharmaceutical's Phase 3 SPACE study reveals Ajovy's significant efficacy in preventing episodic migraines in children aged 6-17. The trial's primary endpoint was met with safety data aligning with adult results. Full findings to be presented later this year.
What's Going On With Recursion Pharmaceuticals Stock Monday?
Recursion Pharmaceuticals shares traded higher Monday after the company provided updated guidance and partnership updates at its Investor Day. The stock is continuing to move higher after hours amid a CNBC appearance from CEO Christopher Gibson.
Will Novo Nordisk Building Fires Serve As A Catalyst For Eli Lilly? Redditors See A Stock Split For US Company 'Very Likely'
Eli Lilly's stock may rise due to supply issues at competitor Novo Nordisk, according to Reddit users. Its weight loss drug and upcoming FDA approval are also factors. Investors are optimistic about its future performance.
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, and COPD medications. This initiative combats tactics hindering generic competition.
Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
Unlock new hope for major depressive disorder with Lumateperone 42 mg. Results from Intra-Cellular's Study 501, show significant symptom relief as adjunctive therapy to antidepressants.
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024.
Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare
2024 Marks a New Era Of Pharmaceutical Innovation
With Covid-19 finally fading into history, the Covid-19 heroes, namely Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE) were forced to redefine their business focus last year, and so, they turned to fighting cancer, the one battle that pharma never se
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches towards the U.S. market. 
Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck
BofA Upgrades Teva Pharmaceutical On Possible Opioid Deal
Prospects of a global opioid deal getting done in 2022 suggest a “potential path to upside” for Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) stock, according to BofA Securities.
Johnson & Johnson Sees A Strong Move: Is It Ready For A Breakout?
Johnson & Johnson (NYSE: JNJ) shares are trading higher Friday after the company agreed to finalize a proposed $26 billion settlement resolving more than 3,000 lawsuits, mainly by state and local governments, seeking to hold it and three other companies responsible for th
Moderna Announces Expanded Supply Agreement With Canada, Initiation Of mRNA Therapeutic Study For Inherited Disorder
Moderna Inc (NASDAQ: MRNA) announced a double dose of positive tidings Monday, but the stock is still wallowing in the red amid a sell-off seen across vaccine stocks.
Jim Lebenthal Likes AbbVie Stock At Its Current Price
It's a great time to invest in pharmaceutical companies such as AbbVie Inc (NYSE: ABBV), Cerity Partners' Jim Lebenthal shared Wednesday on CNBC's "Fast Money Halftime Report."
Johnson & Johnson Reaches $230M Settlement With New York State To End Sale Of Opioids Nationwide
On Saturday, Johnson & Johnson (NYSE: JNJ) said it would end the manufacture and sale of opioids nationwide in a $230 million settlement with the New York state, 
Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning.
Wall Street Crime And Punishment: Philip Musica, The Swindler Who Could Have Been President
Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall that chronicles the bankers, brokers and financial ne’er-do-wells whose ambition and greed takes them in the wrong direction.
Teva Plummets Amid Massive Price Fixing Scheme; Other Generic Drugmakers Also Fall
Corbus Rises Gains After Announcing New Strategic Collaboration With Kaken
;

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved